The Optimal Duration Of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation

Antiplatelet therapy is one of the important targets for coronary heart disease(CHD)treatment,dual antiplatelet therapy(DAPT)has is the cornerstone of coronary heart disease patients after stenting management,Cure and other large-scale clinical trials have been fully confirmed the effectiveness of the dual antiplatelet therapy,but it′s a double-edged sword.DAPT can obviously reduce the risk of cardiovascular events,and simultaneously increase the risk of bleeding.How can we minimize cardiovascular events and bleeding complications? Therefore,optimal duration of dual antiplatelet therapy has become a hot topic in clinical research.With the development of the scaffold,drug-eluting stents(DES)can significantly reduce the restenosis rate compared with bare metal stents(BMS)[1].However,drug-eluting stents cause endothelial delayed arterial healing may be related to late stent thrombosis(ST),which leads to the dual antiplatelet aggregation "grow" phenomenon in a routine.The current clinical guidelines for DAPT duration are still recommended for 12 months.The new P2Y12 receptor inhibitor prasugrel or ticagrelor(in addition to creatinide,clopidogrel)is also emerging.Therefore,the clinical researches on the dual antiplatelet therapy treatment course of different drugs and stents in recent years has been continuously updated.This article mainly summarizes discussion the best DAPT time course of clinical studies.